Show simple item record

dc.contributor.authorChemtai Mungo, Cirilus Ogollah Osongo, Jeniffer Ambaka, Magdalene A Randa, Jackton Omoto, Craig R Cohen, Megan Huchko
dc.date.accessioned2020-09-04T09:21:03Z
dc.date.available2020-09-04T09:21:03Z
dc.date.issued2020-07
dc.identifier.urihttps://repository.maseno.ac.ke/handle/123456789/2724
dc.description.abstractPURPOSE The WHO now recommends thermal ablation as an alternative to cryotherapy within “screen-and-treat” cervical cancer programs in low- and middle-income countries (LMICs). We conducted a safety and acceptability clinical trial of thermal ablation in a Kenyan Ministry of Health hospital among women living with HIV (WLWH; ClinicalTrials.gov identifier: NCT04191967). METHODS Between August 2019 and February 2020, WLWH age 25-65 years underwent human papillomavirus (HPV) self-collection in western Kenya. HPV-positive women underwent visual inspection with acetic acid, biopsy, and treatment with thermal ablation performed by a nonphysician clinician, if eligible by standard guidelines. A questionnaire was administered after treatment to assess for pain and treatment acceptability. Adverse events (AEs) were evaluated 4-6 weeks after treatment with a standardized grading tool. RESULTS A …en_US
dc.publisherAmerican Society of Clinical Oncologyen_US
dc.titleSafety and Acceptability of Thermal Ablation for Treatment of Human Papillomavirus Among Women Living With HIV in Western Kenyaen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record